83
Participants
Start Date
April 2, 2024
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
GT101 injection
GT101 injection to treat cervical cancer
Gemcitabine injection
Gemcitabine injection to treat cervical cancer
RECRUITING
Affiliated Zhongshan Hospital Dalian University, Dalian
RECRUITING
Dalian Medical University First Affiliated Hospital, Dalian
RECRUITING
Harbin Medical University Affiliated Cancer Hospital, Ha’erbin
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Southeast University Affiliated Zhongda Hospital, Nanjing
RECRUITING
Fudan University Affiliated Obstetrics and Gynecology Hospital, Shanghai
RECRUITING
The Fifth Medical Center of the General Hospital of the People's Liberation Army of China, Beijing
RECRUITING
Shandong First Medical University Affiliated Cancer Hospital, Jinan
RECRUITING
Jining First People's Hospital, Jining
RECRUITING
Tianjin Cancer Hospital, Tianjin
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Jiangxi Maternal and Child Health Hospital, Nanchang
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Xiangya Second Hospital of Central South University, Changsha
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
RECRUITING
Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital, Shenzhen
RECRUITING
Guangxi Medical University Affiliated Cancer Hospital, Guilin
RECRUITING
Sichuan University West China Second Hospital, Chengdu
RECRUITING
Yibin Second People's Hospital, Yibin
RECRUITING
Yun Cancer Hospital, Kunming
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
RECRUITING
Shanxi Cancer Hospital, Taiyuan
Lead Sponsor
Grit Biotechnology
INDUSTRY